Monitoring of erlotinib in pancreatic cancer patients during long-time administration and comparison to a physiologically based pharmacokinetic model

Authors: Gruber A, Czejka M, Buchner P, Kitzmueller M, Baroian M, Dittrich C, Hrgovcic A
Publication: Cancer Chemother Pharmacol
Keywords: erlotinib, Food effects, interaction assessment, long-time administration, PBPK model, PBPK modeling kinase inhibitors, therapeutic drug monitoring
Software: ADMET Predictor®, GastroPlus®

Purpose

In this study, a therapeutic drug monitoring (TDM) of erlotinib in pancreatic cancer patients was performed over 50 weeks to reveal possible alterations in erlotinib plasma concentrations. Additionally, a physiologically based pharmacokinetic (PBPK) model was created to assess such variations in silico.